Corona Remedies Revenue and Competitors
Estimated Revenue & Valuation
- Corona Remedies's estimated annual revenue is currently $426.3M per year.
- Corona Remedies's estimated revenue per employee is $201,000
Employee Data
- Corona Remedies has 2121 Employees.
- Corona Remedies grew their employee count by 27% last year.
Corona Remedies's People
Name | Title | Email/Phone |
---|
Corona Remedies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Corona Remedies?
N/A
Total Funding
2121
Number of Employees
$426.3M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Corona Remedies News
2022-04-06 - Fatigue after COVID is way more than just feeling tired. 5 tips on what to do about it
So, understandably, there has been concern around the coronavirus potentially triggering chronic fatigue syndrome. Read more: Explainer: what is...
2022-03-30 - Effect of Early Treatment with Ivermectin among Patients with Covid ...
Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19)...
2022-03-22 - Treatments for coronavirus (COVID-19)
The NHS is offering antibody and antiviral treatments to people with coronavirus (COVID-19) who are at highest risk of becoming seriously ill. The treatments...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $802.5M | 2123 | 9% | N/A |
#2 | $300M | 2124 | N/A | N/A |
#3 | $75M | 2126 | 14% | N/A |
#4 | $713.4M | 2132 | -6% | N/A |
#5 | $627.4M | 2134 | 17% | N/A |